Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darovasertib plus crizotinib versus investigator's choice as first-line therapy for metastatic uveal melanoma
NL-OMON60248Phase 3Active, not recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darovasertib and crizotinib in intraocular melanoma (2 arms), sponsored by IDEAYA Biosciences. Primary endpoints: Dose-exposure-response relationship, Plasma concentration profiles and pharmacokinetic parameters and 4 more. Started Feb 2025; status: active, not recruiting.
02
Drugs
darovasertibcrizotinib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on NL-OMON60248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60248.